Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Discovery & Development Drug Discovery

A New Purpose

It is often said there is no such thing as an original idea – inspiration is always derived from something or someone else. And this is by no means a bad thing. As one example, consider drug repurposing for nasal delivery. This strategy became popular around the mid-nineties with companies wanting to leverage existing drug products through new routes of administration to give them a new lease of life. Nasal delivery was a popular option as its convenience was seen to improve patient compliance and allowed anyone – even a casual bystander – to administer drugs effectively in the event of an emergency. But existing drugs can be repurposed in many other ways as well.
 
Drug repurposing has recently seen a resurgence in the industry – mainly because of economic drivers. The development and commercialization of new drug therapies requires up to 15 years of development work, and can represent around a $2.6 billion investment. Repurposing is cheaper and less complicated, although, as I will discuss later, it remains a complex exercise – and in my view, that complexity is often underestimated. But it is certainly an effective option to avoid extensive development work, and 54 percent of biologics launched or approved in the US in 2017 were for existing drugs repurposed for new disease indications, reformulations or combinations (1). For industry-newcomers and disruptors alike, there is space within the sector for them to make their mark. And with the recent approval of Spravato, an FDA-approved antidepressant adjunct, and Nazolam, a short-acting sedative drug, both repurposed for nasal drug delivery, the playing field is seemingly wide-open.

Read the full article now

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Gerallt Williams

Director Scientific Affairs at Aptar Pharma.

Director Scientific Affairs at Aptar Pharma.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register